The drug company ADDEX together with Dr. Buz Jinnah of Emory University (who serves on our MAB and the Medical and Scientific Advisory Council for DMRF) is launching a trial of a new class of medications known as allosteric modulators. The name of the drug they will use is dipraglurant. It is being studied for possible use with Parkinson’s disease and dystonias.
The study will be a small pilot trial of about 15 patients. The patients will take oral medication and then stay at Emory University for several hours of observation, followed by a second dose. The next day, a third dose will be given. So, participation would require 2 days at Emory University in Atlanta.
If you are interested in participating in this research, please contact Cameron Injoo for further information: firstname.lastname@example.org